title: Mortality risk with dual antiplatelet therapy? - Authors' reply.
authors.affiliation: Dipartimento Cardiovascolare, Policlinico S Orsola, Bologna, Italy.
authors.forename: Tullio
authors.initials: T
authors.lastname: Palmerini
authors.affiliation: Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
authors.forename: Giuseppe Biondi
authors.initials: GB
authors.lastname: Zoccai
authors.affiliation: Cardiac Surgery Department, Oxford Heart Centre, Oxford University, UK.
authors.forename: Umberto
authors.initials: U
authors.lastname: Benedetto
authors.affiliation: Columbia University Medical Center, New York, NY, USA; New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA. Electronic address: gs2184@columbia.edu.
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
mesh_terms: D003324:Coronary Artery Disease / Q000401:mortality* / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D010975:Platelet Aggregation Inhibitors